 |
|
|
| |
Switching From Tenofovir Disoproxil Fumarate and/or Other Oral Antivirals to
Tenofovir Alafenamide in Virally Suppressed Chronic Hepatitis B Patients With Hepatic Impairment: Final 2-Year Efficacy and Safety Results From a Phase 2 Open-label Study
|
| |
| |
EASL International Liver Congress, June 23-26, 2021
Young-Suk Lim,1 Chun-Yen Lin,2 Jeong Heo,3 Ho Bae,4 Wan-Long Chuang,5 Tak Yin Owen Tsang,6 Claire Fournier,7 Aric Josun Hui,8 Huy Trinh,9 Susanna K. Tan,10 Yang Zhao,10 John F. Flaherty,10 Vithika Suri,10 Anuj Gaggar,10 Diana M. Brainard,10 Stephen Ryder,11 Harry Janssen12
1Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea; 2Chang Gung University College of Medicine, Taoyuan City, Taiwan; 3Pusan National University School of Medicine, Pusan National University Hospital, Busan, Republic of Korea; 4Asian Pacific Liver Center, St. Vincent Medical Center, Los Angeles, California, USA; 5Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City, Taiwan; 6Princess Margaret Hospital, Hong Kong;
7Universite de Montreal, Quebec, Canada; 8Alice Ho Miu Ling Nethersole Hospital, Hong Kong; 9San Jose Gastroenterology, San Jose, California; 10Gilead Sciences, Inc., Foster City, California; 11NIHR: Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust, Nottingham, UK; 12Toronto Centre for Liver Disease, Toronto General Hospital, University Health Network, Toronto, Ontario, Canada
References: 1. Agarwal K, et al. J Hepatol 2015;62:533-40; 2. Babusis D, et al. Mol Pharm 2013;10:459-66; 3. Lee WA, et al. Antimicrob Agents Chemother 2005;49:1898-906; 4. Murakami E, et al. Antimicrob Agents Chemother 2015;59:3563-9; 5. Lampertico P, et al. EASL 2020, oral 091; 6. Lampertico P, et al. Lancet Gastroenterol Hepatol. 2020;5:441-53; 7. Lim Y-S, et al. EASL 2020, poster SAT442. Acknowledgments: We extend our thanks to the patients and their families. This study was funded by Gilead Sciences, Inc.
|
| |
|
|
|
|
|
